Active Ingredient History

  • Now
Epelsiban is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist. It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis.   Wikipedia

  • SMILES: CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)c3ccc(C)nc3C)C(=O)[C@H](NC1=O)C4Cc5ccccc5C4
  • Mol. Mass: 518.66
  • ALogP: 2.76
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
3-(2,3-dihydro-1h-inden-2-yl)-1-(1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl)-6-(1-methylpropyl)-2,5-piperazinedione | (3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6- dimethylpyridin-3-yl)-2-(morpholin- 4-yl)-2-oxoethyl)-6- ((1s)-1-methylpropyl)piperazine-2,5-dione | epelsiban | epelsiban besylate | gsk557296 | gsk557296b


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue